Previous 10 | Next 10 |
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company” Nasdaq: LFCR), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has entered into a broad set of ...
Alcon in Action, a company-wide community volunteerism initiative, reinforces the company’s year-round commitment to community engagement and bolsters Alcon’s aspiration to improve lives and strengthen communities Thousands of company associates across 30 countries participa...
2023-05-15 08:24:01 ET Summary Alcon has experienced consistent revenue growth in recent years, the stability of both the company and the industry doesn't warrant a compelling investment case at its current valuation multiples. The eye care industry is a worldwide market that may ...
2023-05-12 16:05:07 ET Summary National Vision Holdings has done well for itself in recent years, and that trend looks set to continue as the company opens more stores. This value-centric brand is quite healthy, and shares are reasonably priced, though not the cheapest. In all...
2023-05-10 13:30:04 ET Alcon Inc. (ALC) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Dan Cravens - VP, IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Anthony Petrone - Mizuho Group Matt...
2023-05-10 08:10:14 ET Alcon Inc. ( NYSE: ALC ) added ~4% pre-market Wednesday as Baird upgraded it to Outperform from Neutral and raised it price target to $90 from $75 per share after the contact lens maker topped Street forecasts with its Q1 2023 financials. The analyst...
2023-05-09 16:32:49 ET Alcon press release ( NYSE: ALC ): Q1 Non-GAAP EPS of $0.70 beats by $0.09 . Revenue of $2.3B (+7% Y/Y) beats by $60M . Net sales of $9.2-$9.4B vs $9.28B consensus EPS of $2.55-$.265 vs $2.60 consensus For further details see: ...
First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency (1) (cc) First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS (2) of $0.70 up 3%, or 14% cc Dividend of CHF 0.21 per share approved by shareholders at the Annual General Mee...
An investigator led, non-interventional study evaluated the performance of two monofocal intraocular lenses (IOLs) in 620 eyes of 310 cataract patients in the U.S. 1 Clareon monofocal IOL provides excellent distance vision, and intermediate vision that is non-inferior to TECNIS Eyhanc...
Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health 1 New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL 2 ...
News, Short Squeeze, Breakout and More Instantly...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Alcon Inc. (NYSE: ALC) traded at a new 52-week high today and are currently trading at $91.69. So far today, approximately 136.09k shares have been exchanged, as compared to an average 30-day volume of 907.93k shares. Alcon Inc., an eye care company, researches, develops, manufactur...